LIMK1

Across TCGA pan-cancer cohorts, LIMK1 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of LIMK1’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where LIMK1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types LIMK1 is over-expressed in tumor, although a few such as COAD show the opposite, repressed pattern.

CCRCC, HNSC, and LUAD are the cancer types where LIMK1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LIMK1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	IV	+0.618	<.001	12	view →
HNSC	All	All	+0.441	<.001	11	view →
LUAD	Female	II,III,IV	+0.492	<.001	8	view →
COAD	All	All	−0.588	.005	5	view →
PDAC	All	All	+0.377	<.001	5	view →
LSCC	All	All	+0.107	<.001	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

LIMK1–CCRCC

Open the CCRCC breakdown →